Economic impact of heart failure with preserved ejection fraction: insights from the ALDO‐DHF trial

by Djawid Hashemi, Ludwig Dettmann, Tobias D. Trippel, Volker Holzendorf, Johannes Petutschnigg, Rolf Wachter, Gerd Hasenfuß, Burkert Pieske, Antonia Zapf, Frank Edelmann
Published 2020-06-01

The diagnostic and prognostic value of galectin‐3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST‐CHF study

by Tobias Daniel Trippel, Meinhard Mende, Hans‐Dirk Düngen, Djawid Hashemi, Johannes Petutschnigg, Kathleen Nolte, Christoph Herrmann‐Lingen, Lutz Binder, Gerd Hasenfuss, Burkert Pieske, Rolf Wachter, Frank Edelmann
Published 2021-04-01

Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial

by Job A. J. Verdonschot, João Pedro Ferreira, Pierpaolo Pellicori, Hans-Peter Brunner-La Rocca, Andrew L. Clark, Franco Cosmi, Joe Cuthbert, Nicolas Girerd, Beatrice Mariottoni, Johannes Petutschnigg, Patrick Rossignol, John G. F. Cleland, Faiez Zannad, Stephane R. B. Heymans, HOMAGE “Heart Omics in AGEing” consortium
Published 2021-08-01